GR3003615T3 - - Google Patents
Info
- Publication number
- GR3003615T3 GR3003615T3 GR920400057T GR920400057T GR3003615T3 GR 3003615 T3 GR3003615 T3 GR 3003615T3 GR 920400057 T GR920400057 T GR 920400057T GR 920400057 T GR920400057 T GR 920400057T GR 3003615 T3 GR3003615 T3 GR 3003615T3
- Authority
- GR
- Greece
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13226288 | 1988-05-30 | ||
| JP1050471A JP2528706B2 (ja) | 1988-05-30 | 1989-03-02 | ジヒドロピリジン化合物の製剤組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3003615T3 true GR3003615T3 (enExample) | 1993-03-16 |
Family
ID=26390939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR920400057T GR3003615T3 (enExample) | 1988-05-30 | 1992-01-22 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4983593A (enExample) |
| EP (1) | EP0344603B1 (enExample) |
| JP (1) | JP2528706B2 (enExample) |
| CA (1) | CA1332152C (enExample) |
| DE (1) | DE68900356D1 (enExample) |
| ES (1) | ES2051920T3 (enExample) |
| GR (1) | GR3003615T3 (enExample) |
| NZ (1) | NZ229309A (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW212139B (enExample) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
| ES2184063T3 (es) * | 1996-03-18 | 2003-04-01 | Nissan Chemical Ind Ltd | Procedimiento de produccion de preparaciones de clorhidrato de efonidipina. |
| CA2231195C (en) * | 1996-07-08 | 2003-01-21 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| EP1741424B1 (en) | 1997-08-11 | 2018-10-03 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailabilty |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US6350786B1 (en) † | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| EP1970052A2 (en) | 1999-02-09 | 2008-09-17 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
| DE60039379D1 (de) | 1999-02-10 | 2008-08-21 | Pfizer Prod Inc | Pharmazeutische feste Dispersionen |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| DE60039802D1 (de) * | 1999-02-10 | 2008-09-25 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| EP1135106B1 (en) * | 1999-09-30 | 2008-04-09 | Penwest Pharmaceuticals Co. | Sustained release matrix systems for highly soluble drugs |
| US7078057B2 (en) * | 1999-12-20 | 2006-07-18 | Kerkhof Nicholas J | Process for producing nanometer particles by fluid bed spray-drying |
| BR0016555A (pt) | 1999-12-23 | 2002-09-17 | Pfizer Prod Inc | Composições farmacêuticas que proporcionam concentrações acrescidas de droga |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| AU2002212102A1 (en) * | 2000-11-08 | 2002-05-21 | Aeromatic-Fielder Ag | A process for production of particles for pharmaceutical compositions having increased bioavailability |
| DE10058772A1 (de) * | 2000-11-27 | 2002-06-06 | Falk Pharma Gmbh | Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen |
| WO2003000235A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| BR0211028A (pt) * | 2001-06-22 | 2004-06-15 | Pfizer Prod Inc | Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
| CA2568007A1 (en) | 2004-05-28 | 2005-12-08 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
| US20080096924A1 (en) * | 2004-12-17 | 2008-04-24 | Ono Pharmaceutical Co., Ltd. | Amorphous Composition |
| JPWO2007029660A1 (ja) * | 2005-09-06 | 2009-03-19 | アステラス製薬株式会社 | 腸溶性基剤が表面に吸着した難溶性薬物の微小粒子 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| US20100240711A1 (en) | 2007-09-21 | 2010-09-23 | Shionogi & Co., Ltd. | Solid preparation comprising npyy5 receptor antagonist |
| JPWO2009072334A1 (ja) * | 2007-12-03 | 2011-04-21 | 富田製薬株式会社 | 製剤用核粒子 |
| EP2291079B1 (en) | 2008-05-14 | 2013-04-24 | Merck Sharp & Dohme Corp. | Formulations for cathepsin k inhibitors |
| JP5511942B2 (ja) | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| US20110064806A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| CA2780190C (en) | 2009-11-06 | 2020-05-05 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX2012014849A (es) | 2010-06-14 | 2013-05-01 | Dow Global Technologies Llc | Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada. |
| SI2672967T1 (sl) | 2011-02-07 | 2018-12-31 | Plexxikon Inc. | Spojine in postopki za kinazno modulacijo in indikacije zanjo |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| AU2012225459A1 (en) | 2011-03-08 | 2013-10-10 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
| US20150182457A1 (en) | 2013-12-31 | 2015-07-02 | Ascendia Pharmaceuticals, Llc | Pharmaceutical Compositions For Poorly Water-Soluble Compounds |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| EP3939591A1 (en) | 2016-06-27 | 2022-01-19 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018175648A1 (en) * | 2017-03-21 | 2018-09-27 | Bioduro, Llc | Gastrointestinal-protective formulations for oral delivery of proteins and peptides |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
| EP4603484A2 (en) | 2019-12-19 | 2025-08-20 | Georgia State University Research Foundation, Inc. | Compounds for the treatment of bacterial infections and potentiation of antibiotics |
| WO2021168320A1 (en) | 2020-02-20 | 2021-08-26 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| EP4216946A4 (en) | 2020-09-23 | 2024-11-13 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5948810A (ja) | 1982-09-10 | 1984-03-21 | Sony Corp | 磁性記録体におけるデ−タのマスク及び再生方法 |
| JPS62123117A (ja) | 1985-11-22 | 1987-06-04 | Nippon Chemiphar Co Ltd | 塩酸ニカルジピン経口用組成物 |
| CN1016063B (zh) * | 1986-01-22 | 1992-04-01 | 日产化学工业株式会社 | 二氢吡啶-5-膦酸环亚丙基酯的制备 |
| IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
-
1989
- 1989-03-02 JP JP1050471A patent/JP2528706B2/ja not_active Expired - Lifetime
- 1989-05-24 ES ES89109381T patent/ES2051920T3/es not_active Expired - Lifetime
- 1989-05-24 DE DE8989109381T patent/DE68900356D1/de not_active Expired - Lifetime
- 1989-05-24 EP EP89109381A patent/EP0344603B1/en not_active Expired - Lifetime
- 1989-05-25 CA CA000600631A patent/CA1332152C/en not_active Expired - Lifetime
- 1989-05-26 NZ NZ229309A patent/NZ229309A/en unknown
- 1989-05-30 US US07/358,144 patent/US4983593A/en not_active Expired - Lifetime
-
1992
- 1992-01-22 GR GR920400057T patent/GR3003615T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ229309A (en) | 1991-06-25 |
| EP0344603A1 (en) | 1989-12-06 |
| CA1332152C (en) | 1994-09-27 |
| JPH0249728A (ja) | 1990-02-20 |
| JP2528706B2 (ja) | 1996-08-28 |
| ES2051920T3 (es) | 1994-07-01 |
| EP0344603B1 (en) | 1991-10-23 |
| DE68900356D1 (de) | 1991-11-28 |
| US4983593A (en) | 1991-01-08 |